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Abstract 
This paper investigates whether firms active in biotechnology can improve their 
technological performance by developing R&D activities in technology clusters. 
Regions that host a concentration of biotechnology activity are identified as 
technology clusters (level of US states, Japanese prefectures and European NUTS2 
regions). A fixed effect panel data analysis on a set of 59 biopharmaceutical firms 
(period 1995-2002) provides evidence for a positive, albeit diminishing (inverted-U 
shape) relationship between the number of technology clusters in which a firm is 
present and its total technological performance. This effect is distinct from a mere 
multi-location effect. 
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  1Introduction 
Corporate activities, especially in knowledge-intensive industries, display a tendency 
to cluster geographically (AUDRETSCH and FELDMAN, 1996; FELDMAN and FLORIDA, 
1994). Following MARSHALL (1920), presence in clusters enhances the innovative 
capacity of firms through the presence of localized knowledge spillovers, and access 
to a pool of highly-skilled labor and specialized suppliers that agglomerate in such 
regions. Innovation dynamics in clusters are further stimulated by the presence of 
local competition and peer pressure among firms (PORTER, 1990). Empirical studies 
stemming from the economic geography literature indeed provide evidence that firms 
located in clusters are more innovative than counterparts located elsewhere (BAPTISTA 
and SWANN, 1998; BATEN et al., 2007; BEAUDRY and BRESCHI, 2003; DEEDS, 
DECAROLIS and COOMBS, 1999; VAN GEENHUIZEN and REYER-GONZALES, 2007). At 
the same time, little is known about the relationship between presence in multiple 
clusters and the overall technological performance of multi-locations firms. Exploring 
this relationship is relevant because firms increasingly organize R&D activities within 
multiple units - located in different regions - to benefit from local agglomeration 
externalities (GASSMAN AND VON ZEDTWITZ, 1999; KUEMMERLE, 1997; GRANSTRAND, 
1999). In this paper, we engage in such analysis by means of a panel dataset of 59 US, 
European and Japanese biopharmaceutical firms (period 1995-2002). The focus of the 
paper is on the relationship between the technological performance of consolidated 
firms (i.e. the parent firm and its subsidiaries) and the number of technology clusters 
in which they develop R&D activities. Clusters are identified at the level of US states, 
European NUTS2 regions and Japanese prefectures as regions with a critical mass of 
technological activities in the field of biotechnology. Whereas previous economic 
geography studies controlled only to a limited extent
1 for the heterogeneity of firms in 
  2terms of innovative efforts and capabilities, this study uses fixed effect panel data 
techniques and include controls for time-varying firm differences in R&D 
expenditures and past experience. This allows to distinguish cluster presence from 
firm-specific performance effects (BEUGELSDIJK, 2007). The analyses confirm the 
presence of an inverted-U shape relationship between the number of technology 
clusters in which a firm is present and its total technological performance. This effect 
is distinct from a mere multi-location effect. 
The remainder of the paper is organized as follows. First, an overview of prior 
research on clusters and firm performance is provided, resulting in hypotheses on the 
relationship between cluster presence and firm’s technological performance. Next, the 
data sources and variables used in this study are presented, followed by the empirical 
results. Conclusions, limitations and directions for further research are discussed in 
the final section. 
 
Industry and technology clusters 
The clustering of industrial activity in well-defined and relatively small geographic 
areas has been observed for long time by economic geographers and regional 
scientists (e.g. MARSHALL 1920; KRUGMAN 1991; PORTER 1990). Famous examples 
of industrial clusters include Detroit’s car manufacturing industry, the entertainment 
industry of Hollywood and the fashion industry in northern Italy. Clustering remains a 
striking feature of national and regional economies, despite the availability of better 
transportation and communication infrastructure and the presence of global markets 
from which capital, talent and technology can be sourced (PORTER, 1998; 2000). 
Following the success of Silicon Valley in California and Route 128 in Boston 
(SAXENIAN, 1994), there has been a wide interest of researchers and policy makers in 
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clusters, where inter-firm connections are predominantly vertical, technology clusters 
exhibit a more lateral structure consisting of direct and indirect competitors 
developing diversified applications of the same core technology within different 
markets or industries (ST. JOHN and POUDER, 2006). Value dynamics in technology 
clusters or “technology districts” build on unique technological resources - the 
technological infrastructure - which supports firms’ innovation activities (FELDMAN et 
al, 1994; STORPER, 1992). Sources of knowledge in technology clusters are diverse, 
ranging from universities and public research institutes to firms, suppliers and 
customers. 
MARSHALL (1920) highlighted three incentives for firms to cluster 
geographically: (i) broader access to specialized, highly-skilled labor; (ii) access to 
specialized suppliers; and (iii) the presence of inter-organizational knowledge 
spillovers among similar firms
2. The broad concept of knowledge spillovers is 
probably the most frequently invoked source of agglomeration economies (HEAD et 
al, 1995) and has been widely investigated in literature (e.g. DÖRING and 
SCHNELLENBACH, 2006; BRESCHI and LISSONI, 2001). Knowledge spillovers arise 
through labor mobility (ALMEIDA and KOGUT, 1999) and exchange processes 
involving competitors, suppliers, customers and providers of professional services 
(VON HIPPEL, 1988; ROSENKOPF and ALMEIDA, 2003). They can be considered as an 
externality which allows firms to achieve similar R&D results faster and/or with 
fewer resources. Empirical work has shown the existence and geographically bounded 
nature of knowledge spillovers (JAFFE et al., 1993; ALMEIDA and KOGUT, 1999; 
VARGA, 2000; RODRÍGUEZ-POSE and CRESCENZI, 2008). Spillovers are more local to 
the extent that the relevant knowledge base is tacit (POLANYI, 1966; NONAKA, 1994; 
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biotechnology (LECOCQ and VAN LOOY, 2009). PORTER (1990; 1998) provided two 
additional reasons why firms located in clusters are more innovative than firms 
located outside clusters. First, opportunities for innovation (both new buyer needs and 
new technological opportunities) are more visible in clusters. Next, competitive 
and/or peer pressure among local firms stimulates firms to be more innovative and 
increases the efficiency of their operations.  
While clusters are often associated with positive effects on firm performance, 
potential disadvantages can be noticed as well. First, costs of resources (e.g. labor, 
real estate, professional services) might be significantly higher in clusters due to 
congestion effects (BEAUDRY & BRESCHI, 2003). In addition, cluster membership 
might lead to an inward orientation whereby relevant developments situated outside 
the cluster are neglected (PORTER, 1998). Finally, firms located in clusters might be 
confronted with higher levels of unintended (outward) knowledge spillovers, affecting 
the firm’s competitive advantage in a negative way (SHAVER and FLYER, 2000). 
While such disadvantages might occur, they are not directly relevant for the research 
questions addressed in this paper as the focus is on the firm’s technological 
performance (as opposed to the overall competitive position of the firm or the 
efficiency implications of being present in clusters).  
 
 
Clusters and Firm Performance 
The capacity of firms to innovate is not limited to the boundaries of the firm and 
increasingly depends on external resources that agglomerate in specific places 
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essential characteristic of clusters, the beneficial effects from being present in a 
cluster should manifest themselves in the first place on the innovative output of firms 
rather than on the firm’s financial or growth performance (BAPTISTA and SWANN, 
1998). Studies in the economic geography literature have investigated whether firms 
(plant level) located in an industrial or technological cluster are more innovative than 
firms outside clusters
3.
 These studies can be classified in two groups based on the 
methodologies used to measure clusters. 
A first set of studies investigated whether firms located in industrial clusters 
are more innovative. The concentration of industrial activity in a region is measured 
by sector level employment data. BAPTISTA and SWANN (1998) found a positive effect 
of own sector employment in the region on the likelihood of manufacturing firms in 
the United Kingdom to innovate. In contrast, BEAUDRY and BRESCHI (2003) found no 
effect of own sector employment on firms’ innovative performance for a sample of 
UK and Italian firms. Only the concentration of innovative firms (and the size of their 
accumulated knowledge base) in the own industry was found to positively impact the 
technological performance of firms. Similar results were found in the study of BATEN 
et al. (2007) for firms trading in the state of Baden (Germany) around 1900. These 
findings suggest that for firms’ innovative performance, the presence of critical mass 
in terms of knowledge creation activities in a region is more important than the 
overall industrial activity per se.  
A second set of studies classified regions in clusters and non-clusters based on 
the amount of technological activity observed in the region, and examined whether 
firms located in technology clusters are more innovative than firms located elsewhere. 
DEEDS et al. (1999) classified eight regions in the United States (MSA level), that host 
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firms located in clusters are more innovative than firms located outside the clusters. 
For the Netherlands, VAN GEENHUIZEN and REYER-GONZALES (2007) defined clusters 
as regions with at least one knowledge institute and 10 young entrepreneurial 
biotechnology firms. Their analyses showed no significant effect from cluster location 
on the innovativeness of biotechnology firms. However, when only the largest and 
oldest biotechnology cluster in the Netherlands - the Leiden region - is considered, 
cluster presence had a significant positive effect on firm performance. These results 
suggest that a critical mass of technological activity is needed before positive cluster 
effects can be observed at level of the firm. 
Aforementioned economic geography studies, used cross-sectional data at the 
level of single plants to investigate whether clusters are supportive to firms’ 
innovation activities. While the results indicate that firms in clusters are more 
innovative than firms located elsewhere, they do not provide evidence whether firms 
can improve their technological performance by extending their presence within 
multiple clusters. This research question is addressed in this paper. More specifically, 
the relationship between the number of technology clusters in which a firm is present 
and its total technological performance is studied. Exploring this relationship is 
relevant because firms increasingly organize R&D activities within multiple units – 
located in different regions- to benefit from agglomeration externalities (GASSMAN 
and VON ZEDTWITZ, 1999; KUEMMERLE, 1997; GRANSTRAND, 1999). R&D location 
choices are not confined to national borders, but take place on a global scale. As such, 
empirical analyses assessing the impact of cluster presence should not be limited to 
one particular country or region, but consider technology clusters on a more global 
scale. Likewise on the firm level, studying the impact of cluster presence requires 
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subsidiaries). 
In this paper, such an analysis is performed by means of a panel dataset on the 
technological activities of 59 US, European and Japanese biopharmaceutical firms 
(1995-2002). In line with economic geography studies, locations of firms’ R&D 
activities (including cluster presence) are analyzed at the regional level (US states, 
European NUTS2 regions and Japanese prefectures). Technology clusters are defined 
as worldwide leading regions in technology development. The models in this study 
control for firm-level heterogeneity in innovative efforts and capabilities by 
employing fixed effects panel data techniques and including firm-level controls on 
R&D expenditures and innovation experience. This allows to clearly distinguish 
between cluster presence and firm-specific performance effects (BEUGELSDIJK, 2007).  
A positive effect on a firm’s overall technological performance is expected 
from being present in multiple clusters, as this coincides with an increased access to 
state-of-the-art knowledge available within each of these regions. At the same time, 
the more one is already involved in different clusters, the smaller the additional 
effects in terms of access to new, relevant knowledge might become. In addition, the 
costs of coordinating multiple R&D units and leveraging and integrating knowledge 
from multiple locations will increase with the number of locations in which a firm is 
present. Building on the aforementioned research, it is expected that location benefits 
principally stems from presence in technology clusters with a critical mass of relevant 
knowledge, as opposed to other regions. Therefore, the effects of cluster membership 
on the overall technological performance of firms should be distinctive from a mere 
multiple location effect. The following hypotheses are guiding the empirical study: 
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their presence in technology clusters. 
Hypothesis 2: Firms extending their presence in technology clusters will gain 
additional benefits in terms of technological performance, albeit of a 
diminishing  nature (inverted U-shape relationship). 
Hypothesis 3: The relationship between cluster membership and overall technological 
performance is distinct from a mere multi-location effect. 
 
 
Data and methodology 
Panel data on the technological activities of 59 biopharmaceutical firms with parent 
firms located in the United States, Europe and Japan, have been collected to study the 
relationship between the location of R&D activities in multiple clusters and regions 
and the overall technological performance of firms. Patent data is used to create 
indicators of firms’ technological activities (location and performance) and to identify 
biotechnology clusters on a global scale (US states, NUTS 2 regions in Europe and 
prefectures in Japan). The use of patent data has several advantages (PAVITT, 1985; 
GRILICHES, 1990). They are easy to access, cover long time series and contain detailed 
information on the technological content, owners and inventors of patented 
inventions. This allows to mark out biotechnology patents, construct indicators of the 
technological performance of firms and regions and identify the locations where 
inventions took place.  At the same time, patent indicators also have some deficits: not 
all inventions are patented, patent propensities vary across industries and firms, and 
patented inventions vary in technical and economic value (MANSFIELD,  1986; 
GAMBARDELLA  et al,  2008). One can lessen these problems by restricting patent 
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(ARUNDEL and KABLA, 1988), and by weighting patent counts (technological 
performance indicator) by the number of forward citations received (HALL et al, 
2005). Despite their shortcomings, there is simply no other indicator that provides the 
same level of detail on firms’ technological activities as patents do (GRILICHES, 
1990). Further, studies have found a strong correlation between patent counts and 
other technology indicators (e.g. new product announcements and expert opinions) on 
the level of firms (HAGEDOORN and CLOODT, 2003; NARIN and NOMA, 1987) and 
regions (ACS et al, 2002), establishing patents as a valid indicator of novel 
technological activity.  
In this study, patent indicators are based on data from the European Patent 
Office (EPO). The choice for EPO rather than US Patent and Trademark (USPTO) 
patents is motivated by two factors. First, EPO patents are considered to be, on 
average, of a higher quality than USPTO patents as the cost of patenting is two to five 
times higher at EPO than USPTO, and EPO has a 20-30 percent lower patent granting 
rate than USPTO (VAN  POTTELSBERGHE DE LA POTTERIE and FRANÇOIS, 2006; 
QUILLEN and WEBSTER, 2001). Second, inventor address information on USPTO 
patents – used to identify the location of R&D activities – is incomplete for a large 
number of USPTO patents. As a result, these patents can not be assigned to US states, 
European regions or Japanese prefectures. For the analyses, patent application data 
rather than patent grants are used because of the extensive time periods observed 
between application and granting decisions at the European Patent Office (especially 
for biotech)
4. 
The geographic location of inventions is identified via inventor address 
information. Allocation based on inventor addresses is the most commonly used 
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assignee addresses might signal the location of corporate headquarters rather than 
research laboratory where the invention took place (DEYLE and GRUPP, 2005; KHAN 
and DERNIS, 2006). The use of inventor addresses may however also introduce some 
bias since inventors may not live in the same region as they work. LANDONI et al. 
(2008) performed a validation exercise where both allocation methods (inventor and 
applicant addresses) are compared with the real R&D locations of inventions. Their 
work confirmed the superiority of the inventor’s address criterion, especially for 
patent statistics at a disaggregated geographical level (NUTS2 and NUTS3).   
 
Sample of Biopharmaceutical Firms 
Parent firms with the largest biotech patent portfolio are identified from a dataset with 
all EPO patent applications in the field of biotechnology (time period 1978-2001). 
This dataset is the result of a study by GLÄNZEL et al. (2004) to delineate 
technological activity in the field of biotechnology
5. The selected firms are active in 
different sectors: mostly in biotechnology, the pharmaceutical or chemical industry, 
but the list of parent firms also includes producers of consumer products, energy 
concerns and breweries. For consistency of the sample, only the biopharmaceutical 
firms (75 largest patenting firms) were retained. Due to missing financial data on firm 
controls and / or incomplete information on the group structure of parent firms, the 
list of firms was further reduced to 59 biopharmaceutical firms. All these firms have 
headquarters in the United States, Japan or Europe (EU-15 and Switzerland). 
Appendix 1 contains a complete list of the firms under study.  
For this sample of 59 biopharmaceutical firms, patent data were collected at 
the consolidated parent level, i.e. comprising headquarters and all (majority-owned)
6 
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changes in the group structure of the 59 parent firms due to acquisitions, mergers, 
green-field investments and spin-offs during the period 1995 to 2002. For this 
purpose, yearly lists of subsidiaries included in annual reports were used, as well as 
yearly 10-K reports filed with the SEC in the US and, for Japanese firms, information 
on foreign subsidiaries published by Toyo Keizai in the yearly Directories of Japanese 
Overseas Investments. Using consolidated patent data is important to get a complete 
picture of firms’ technological activities as a significant part of large firms’ patents 
are not filed under the parent firm name (LETEN et al, 2007). Firm financial data are 
also collected at the consolidated firm level via corporate annual reports, Worldscope 
and Compustat financial databases.  
Biotechnology Clusters 
Biotechnology is a knowledge-intensive technology field, which from its origin has 
developed within a limited number of regions of excellence, such as California and 
the Boston area in the United States, and Cambridge in the United Kingdom. To 
identify biotechnology clusters worldwide, the dataset with all EPO patent 
applications in the field of biotechnology created by GLÄNZEL et al. (2004) is used. 
The dataset shows that, for the period 1990-1999, almost all patenting activity in the 
domain of biotechnology (94%) takes place in the United States, Europe (EU-15 and 
Switzerland) and Japan. In this study, the focus is therefore on regions in the United 
States, Europe and Japan
7.  
Regions are defined at the level of following national subdivisions: European 
NUTS 2 regions (n=220), US states (n=50), and Japanese prefectures (n=47). The 
NUTS classification
8 provides a breakdown of European countries into regions, 
primarily based on institutional divisions currently in force in the country. The limits 
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and maximum thresholds for the average population size of the regions are 
respectively 800.000 and 3 million. The United States of America consist of 50 sub-
national entities called states, having their own state government with substantial state 
responsibilities. The population in the US states varies from 500,000 to 36 million. 
The prefectures of Japan consists of 47 sub-national jurisdictions with an own 
governor and parliament. The size of prefectures vary between 600,000 and 12 
million inhabitants. Cluster boundaries do not necessarily coincide with the 
boundaries of administrative regions. Clusters may well spread over more than one 
region (e.g. the tri-state cluster in the states of New York, New Jersey and 
Pennsylvania and the cluster covering the prefectures of Tokyo and Kanagawa). 
Alternatively, regions may enclose more than one cluster (e.g. the triangle San 
Francisco - San Jose - Sacramento, better known as Silicon Valley, and the region 
between Los Angeles and San Diego in the state of California). Despite these 
concerns, an analysis of regions coinciding with the boundaries of the administrative 
subdivisions (US states, European NUTS 2 regions and Japanese prefectures) was 
chosen
9, as it is believed that they provide comparable regional units of analysis.  
The amount of biotechnological R&D activities in a region is measured by the 
number of EPO patents in that regions during the period 1990-1999. Patent 
applications are allocated to regions based on inventor addresses. When a patent 
contains multiple inventors in different regions, the patent is fully counted in each 
region. Table 1 shows the 50 regions with the highest technological performance in 
the field of biotechnology. VAN GEENHUIZEN and REYER-GONZALES (2007) showed 
that agglomeration effects only take place in regions that host a minimum critical 
mass of technological activity. In line with this observation, a region is defined as a 
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applications in the field of biotechnology. Ten regions satisfy this condition. Together 
they account for 45% of biotechnology patents worldwide. Most biotechnology 
clusters are located in the United States, with a clear supremacy of the state of 
California, which account for almost 15% of all biotechnology patents. Other regions 
with a substantial amount of activity in biotechnology are Massachusetts, Maryland, 
Pennsylvania, New York and New Jersey. Europe has one top region located in 
France (the region of Paris). With Tokyo, Kanagawa and Osaka, Japan counts three 
top regions in biotechnology.  
 
------------------------------ 
Insert Table 1 about here 
------------------------------- 
 
Firm Variables and Model 
Dependent Variable 
The dependent variable in the study is the technological performance of firms in 
biotechnology. This is measured by the number of biotech patent applications applied 
by a firm in a certain year, weighted by the number of forward patent citations 
received over a fixed four year time window. The ‘weighting’ is done to control for 
variation in the technological and economic importance of patented inventions 
(HARHOFF et al., 1999; TRAJTENBERG, 1990; HALL et al, 2005)
10. The dependent 
variable is a count variable with only non-negative integer values. In this case, non-
linear count data models are preferred to standard linear regression models as the 
former explicitly take into account the non-negativity and discreteness of the 
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the study allow for overdispersion in the dependent variable. To control for the 
presence of unobserved firm-specific effects (which may correlate with, and bias the 
effect of explanatory variables in the models, if not controlled for), fixed effects panel 
data estimators are used. This estimation technique removes (time constant) 
unobserved firm-specific factors by time-demeaning all variables (dependent and 
explanatory) before performing regressions.  
 
Presence in Technology Clusters 
To identify the regions in which firms are present, inventor address information on the 
biotechnology patents of the firms is used.  More specifically, a firm  is considered to 
have undertaken biotechnology R&D activities in a region if the firm has at least two 
inventors residing in that region during the last two years. Given the fact that R&D 
collaboration is quite widespread in the field of biotechnology (LECOCQ and VAN 
LOOY, 2009), it was decided to consider presence in a region only on the firm’s fully 
owned patents, thus reflecting the number of regions (clusters and other regions) in 
which a firm is present through its fully owned or single parent patents. For co-owned 
patents, i.e. patents with multiple assignees from different parent organizations, it is 
not possible to identify to which assignee an inventor belongs. Therefore using 
inventor address information on such patents may not only pick up a firm’s own R&D 
locations, but also the R&D locations of co-assignees.  
Three indicators related to the location of the biotechnology R&D activities of 
a firm are created: (i) clusters, reflecting the number of R&D biotechnology clusters 
in which a firm is present, (ii) other regions, reflecting the number of other regions, 
not defined as clusters, in which a firm undertakes R&D activities, and (iii) countries, 
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11. To test for non-linear 
relationships between the R&D location variables and the firm’s overall technological 
performance, both linear and squared terms of the location variables are included in 
the empirical models. Applying fixed effect panel data models require that there is 
enough within-firm variation in the number of R&D locations over time. This is the 
case for the sample firms, as they all engaged in M&A activities, opened new 
laboratories and/or close down existing ones over the time period 1995-2002.  
 
Control Variables 
Several (time varying) variables that might affect the technological performance of 
firms are included as controls in the analyses. First, an indicator for the size of a 
firm’s existing technology portfolio in biotech is included, measured by the number of 
biotech patents applied for by the firm in the last 5 years. Firms with large technology 
portfolios are more experienced in innovation, and may be better positioned to 
develop new technological competences (NESTA and SAVIOTTI, 2006). In previous 
studies, a time period of 5 years has been considered as appropriate for assessing the 
validity of knowledge bases in a given technology (STUART and PODOLNY, 1996; 
AHUJA and LAMPERT, 2001). Second, differences in the size of firms’ R&D effort are 
included, measured by one-year lagged R&D expenditures
12. Firms that have more 
R&D resources, are expected to have a higher technological performance. Third, year 
dummies are included in the models to control for changes over time in the propensity 
of firms to patent.  
Descriptive statistics and correlation coefficients for the dependent and 
explanatory variables are reported in table 2. The mean (yearly) number of citation-
weighted patents for the firms in the sample is 20, and firms’ average R&D 
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average, present in 1.6 biotechnology clusters and 2.6 other regions, spread over 2 
countries. None of the reported correlations are excessively high. 
 
----------------------------------------- 




The results of the fixed effects negative binomial models on the relation between 
cluster membership and firms’ overall technological performance are presented in 
Table 3. Model 1 is the baseline model including the control variables. Both the 
lagged biotech patent portfolio and the R&D expenditure variable are positive and 
significant. In model 2, the cluster variable is introduced, which indicates the number 
of clusters in which a firm develops R&D activities. The cluster variable is positive 
and significant, indicating that firms can enhance their technological performance by 
performing R&D activities in technology clusters (confirming hypothesis 1). In model 
3, the other regions variable is added to the set of control variables, reflecting the 
number of regions, outside clusters, in which a firm develops R&D activities. This 
variable is not significant. In addition, the log likelihood ratio test reveals that 
including the other region variable does not add significantly to the explanatory power 
of the baseline model (Chi2 LR test = 0.60). Model 4 includes both the cluster and 
other regions variables. A positive and significant coefficient is found for the cluster 
variable, while the coefficient of the other regions variable remains insignificant. 
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clusters, and not in other regions, has a positive impact on the technological 
performance of firms. 
 
----------------------------------------- 
Insert Table 3 about here 
  ------------------------------------------ 
 
Model 5 is the most complete model and includes, besides the linear terms, 
also the quadratic terms of the cluster and the other regions variables. Including 
quadratic terms allows to check for non-linear relationships between the location 
variables and firm performance. The log likelihood ratio test indicates that model 5 
significantly adds to model 4 in terms of explanatory power (Chi2 LR test 
=11.04***). The cluster variable has a positive and significant linear term, and a 
negative and significant quadratic term. This confirms hypothesis 2: there is an 
inverted U-shape relationship between the number of technology clusters in which 
firms develop R&D activities and their total technological performance. The 
coefficients of the cluster variables in model 5 further indicate that biopharmaceutical 
firms should – ideally – be present in 4 biotechnology clusters. Since the average 
biopharmaceutical firm in the sample is present in less than 2 biotech clusters, most 
firms can still improve their technological performance by setting up R&D activities 
in additional biotechnology clusters
13. In line with previous models, no significant 
effects are found for the other regions variables in model 5. Taken together, the 
findings show that presence in technology clusters, and not presence in other 
  18locations, has a significant effect on firms’ technological performance (confirming 
hypothesis 3).  
In model 6, an additional regression is ran to check whether the cluster effect 
is distinctive from a R&D internationalization effect. Therefore, the linear and 
quadratic term of the countries variable are added to the base line model, reflecting 
the number of countries in which a firm is present. The countries variables are not 
significant, and the model does not significantly improve compared to the baseline 
model containing only the control variables (Chi2 LR test = 0.95). This again 
confirms hypothesis 3 that presence in multiple technology clusters and not the mere 
presence in multiple locations, is contributing to firms’ technological performance. 
 
Conclusions 
Firms active in knowledge-intensive fields such as biotechnology, are increasingly 
developing global R&D activities, with location choices for an important degree being 
determined by the presence of local technological capabilities. Studies in the 
economic geography literature have shown that firms located in regions where 
technological activities agglomerate (technology clusters), are more innovative than 
firms located elsewhere (BAPTISTA and SWANN, 1998; BEAUDRY and BRESCHI, 2003; 
DEEDS, DECAROLIS and COOMBS, 1999; VAN G EENHUIZEN and REYER-GONZALES, 
2007; BATEN et al., 2007). However, so far, little is known about the impact of 
presence in multiple clusters and regions on the technological performance of multi-
location firms.  
In this study, such an analysis is performed, based on a panel dataset (period 
1995-2002) of 59 biopharmaceutical firms with headquarters in the United States, 
Europe or Japan. Firm-level differences in innovative capabilities are taken into 
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innovation experience. Biotechnology clusters are defined as worldwide leading 
regions in terms of technology development in the field of biotechnology. The study 
provide evidence for an inverted U-shape relationship between the number of 
technology clusters in which a firm is present and it’s total technological 
performance.  
The findings suggest that biopharmaceutical firms can enhance their 
technological performance by developing R&D activities in multiple technology 
clusters. The results also reveal that boundaries exist in terms of the net beneficial 
effects of spreading R&D activities over multiple locations. When the number of 
clusters in which a firm is carrying out R&D activities becomes too large, increasing 
costs in terms of coordinating and integrating geographically dispersed R&D units 
might start to prevail over the marginal benefits from getting access to new, relevant 
knowledge. At the same time, the observed diminishing effects might also be caused 
by insufficient critical mass in terms of technological activity (economies of scale and 
scope) when R&D activities are over-dispersed.  
The analyses provide evidence that the cluster effect is distinctive from a mere 
multi-location effect: the presence in technology clusters, and not the presence in 
multiple regions and countries, is contributing to a better technological performance 
of firms. As such, the study provides interesting insights for the R&D 
internationalisation literature. Recently, this stream of literature started to investigate 
the relationship between the geographical dispersion of firms’ R&D activities and 
firm performance. Some studies (SINGH, 2008; FURMAN et al, 2006) found negative 
effects, while other studies (CRISCUOLO and AUTIO, 2008; IWASA and ODAGIRI, 2004; 
PENNER-HAHN and SHAVER, 2005; TODO and SHIMIZUTANI, 2008) found positive 
  20effects of geographical dispersion on firms’ performance. These studies did not take 
into account the technological characteristics of regions in which R&D activities are 
deployed (clusters or non-cluster regions)
14. This may be one factor explaining their 
mixed results. 
Further investigating aforementioned potential drivers of the observed 
declining effect of cluster membership on firm performance might be an interesting 
area for further research. Within this study, the focus was on regional technological 
capabilities within the same field (biotechnology); as such, a natural extension of the 
research reported here implies an examination of ‘Jacobs’ externalities as well: what 
is the impact of regional capabilities situated within different technological fields on 
the performance of firms? Finally, within this analysis, the micro-dynamics 
underlying the observed positive technological performance effects were treated as a 
‘black box’. While the findings are interesting within the framework of R&D location 
decisions, identifying the most effective mechanisms (e.g. collaboration with local 
firms and/or research institutes, technology acquisition, researcher mobility,…) 
through which firms can benefit from agglomeration externalities in technology 
clusters might be highly relevant to ensure that firms yield results once location 
decisions have been made. We do hope that our analysis and findings inspire 
colleagues in the fields of economic geography and R&D internationalisation to 
engage in such endeavours. 
  21Appendix 1: List of biopharmaceutical firms 
 
Abbott Laboratories  Innogenetics 
Affymetrix Inc.  Invitrogen 
Ajinomoto  Isis Pharmaceuticals Inc 
Amgen Johnson  Johnson 
Applera  Kyowa Hakko Kogyo 
Astrazeneca Lonza  Ag 
Aventis Martek  Biosciences 
Beckman Coulter  Maxygen Inc 
Becton Dickinson And Company  Merck Co 
Biogen Idec  Merck Kgaa 
Boehringer Ingelheim  Millennium Pharmaceuticals 
Bristol Myers Squibb  Mochida Pharmaceutical 
Cell Genesys Inc  Myriad Genetics Inc 
Chiron Nanogen  Inc 
Diversa Corp  Novartis 
Eli Lilly  Novo Nordisk As 
Fujisawa Pharmaceutical  Pfizer 
Gen Probe Inc  Regeneron Pharmaceuticals 
Genelabs Ribozyme  Pharmaceuticals 
Genencor Schering 
Genentech Inc  Schering Plough 
Genzyme Scios  Inc 
Geron Corp  Seikagaku 
Gilead Sciences  Sequenom Inc 
Heska Ag  Shionogi 
Human Genome Sciences  Solexa 
Hybridon Tanox  Inc 
Icos Corporation  Transgene 
Idexx Laboratories  Wyeth 
Incyte Corporation   
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1 Prior studies used cross-sectional data analysis techniques, and did not control for 
differences in firms’ innovation efforts (absolute level of R&D expenses) when 
studying the impact of cluster membership on firms’ technological performance.  
2 MARSHALL (1920), ARROW (1962) and ROMER (1986) (henceforth M-A-R) suggest 
that knowledge spillovers mainly arise among firms in the same industry. On the 
contrary, JACOBS (1969) believes that the most important knowledge spillovers occur 
across industries. Empirical results on the relative importance of both type of 
knowledge externalities are mixed (see for example GLAESER et al, 1992; FELDMAN 
and AUDRETSCH, 1999; HENDERSON et al, 1995; BEAUDRY   and SCHIFFAUEROVA, 
2009; FRENKEN et al, 2007).  
3 Other studies (ex. HILL and NAROFF, 1984; SWANN and PREVEZER, 1996 and 
HENDRY and BROWN, 2006 ) have studied the impact of cluster location on the 
financial performance and growth of firms. 
4 We calculated that for EPO biotechnology patents applied for in 1995 and granted 
by 2006, only 40% of the patents were granted within 6 years after application.  
5 GLÄNZEL et al. (2004) defined and validated a search key to retrieve all EPO patents 
in the biotechnology domain in the period 1978-2001.  
6 A subsidiary is considered as majority owned if the parent firm holds at least a 50% 
share in the subsidiary. 
7 Note that no other region outside the United States, Europe (EU-15 and Switzerland) 
and Japan has sufficient patent applications to qualify as a cluster.  
8 NUTS stands for Nomenclature of Territorial Units for Statistics and is the three-
level hierarchical classification of regions established by Eurostat. 
9 Analyses in which we combine administrative subdivisions to better follow the 
actual boundaries of biotechnology clusters, yield similar results.  
10 The number of citations received by a patent correlates significantly with indicators 
of patent value such as patent renewal rates (HARHOFF et al., 1999), consumer-surplus 
generated (TRAJTENBERG, 1990) and expert evaluation (ALBERT et al., 1991).  
11 Analogous to the cluster and other regions variables, we only count countries from 
EU-15, Switzerland, US and Japan. 
12 Firm level R&D expenses specifically related to biotechnology activities are not 
available.  
  24                                                                                                                                            
13 Only in 5.45% of the observations (firm-year), firms develop biotech activities  in 
more than 4 technology clusters.  
14 Notable exception is IWASA and ODAGIRI (2004). They take into account the local 
technological strengths of US states in which the US subsidiaries of Japanese 
manufacturing firms are located.  
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  33Table 1 Top Biotechnology regions (period 1990-1999) 
  
Region  Country  Patents  %  Cum % 
1  California  United States  4,162  15.4%  15.4% 
2  Massachusetts  United States  1,853  6.8%  21.6% 
3  Maryland  United States  1,285  4.7%  25.5% 
4  Pennsylvania  United States  1,264  4.7%  29.6% 
5  New York  United States  1,072  4.0%  32.8% 
6  New Jersey  United States  1,005  3.7%  34.9% 
7  Tokyo  Japan  916  3.4%  38.2% 
8  Île de France  France  873  3.2%  41.1% 
9  Kanagawa  Japan  724  2.7%  42.8% 
10  Osaka  Japan  672  2.5%  44.9% 
11  Denmark  Denmark  643  2.4%  47.1% 
12  Washington  United States  619  2.3%  48.8% 
13  Oberbayern  Germany  593  2.2%  50.8% 
14  Illinois  United States  473  1.7%  52.1% 
15  East Anglia  United Kingdom  463  1.7%  53.6% 
16  Texas  United States  446  1.6%  54.7% 
17  Darmstadt  Germany  443  1.6%  56.1% 
18  Berkshire, Buckinghamshire and Oxfordshire  United Kingdom  434  1.6%  57.4% 
19  North Carolina  United States  416  1.5%  58.4% 
20  Zuid-Holland  Netherlands  410  1.5%  59.7% 
21  Indiana  United States  406  1.5%  60.9% 
22  Ibaraki  Japan  394  1.5%  61.8% 
23  Hyogo  Japan  394  1.5%  62.3% 
24  Connecticut  United States  385  1.4%  63.1% 
25  Kyoto  Japan  377  1.4%  63.6% 
26  Rhône-Alpes  France  339  1.3%  64.5% 
27  Wisconsin  United States  320  1.2%  65.2% 
28  Inner London  United Kingdom  319  1.2%  66.0% 
29  Saitama  Japan  317  1.2%  66.4% 
30  Ohio  United States  308  1.1%  67.2% 
31  Karlsruhe  Germany  305  1.1%  67.9% 
32  Köln  Germany  292  1.1%  68.7% 
33  Missouri  United States  280  1.0%  69.3% 
34  Chiba  Japan  276  1.0%  69.6% 
35  Michigan  United States  265  1.0%  70.3% 
36  Iowa  United States  261  1.0%  70.9% 
37  Berlin  Germany  258  1.0%  71.7% 
38  Colorado  United States  251  0.9%  72.2% 
39  Shizuoka  Japan  245  0.9%  72.7% 
40  Région lémanique  Switzerland  239  0.9%  73.4% 
41  Nordwestschweiz  Switzerland  234  0.9%  74.0% 
42  Delaware  United States  232  0.9%  74.3% 
43  Minnesota  United States  213  0.8%  74.8% 
44  Düsseldorf  Germany  213  0.8%  75.1% 
45  Virginia  United States  211  0.8%  75.3% 
46  Florida  United States  207  0.8%  75.7% 
47  Noord-Holland  Netherlands  199  0.7%  76.1% 
48  Prov. Vlaams-Brabant  Belgium  192  0.7%  76.6% 
49  Shiga  Japan  191  0.7%  76.7% 
50  Lombardia  Italy  191  0.7%  77.3% 
Cumulative % excludes double counts due to co-patenting in multiple regions
  34       Biotech Biotech  R&D Clusters Other   Countries 
 Obs  Mean  Std.  Dev.  patents  portfolio      regions   
Weighted number of Biotech patents  422             21.1             36.2  1 
35 
      
Size of Biotech Patent Portfolio (5year)  422             57.2             61.9  0.4834  1       
    
  
R&D Expenditures (in thousands USD)  422           452.4           760.3  0.0681  0.4350  1 
Number of clusters  422               1.6               1.5  0.3260  0.5985  0.3983  1 
Number of other regions  422               2.6               3.3  0.1181  0.4977  0.5458  0.3865  1   
Number of countries  422               2.0               1.5  0.0930  0.4257  0.5579  0.3455  0.7729  1 







 Table 3 Fixed Effect Negative Binomial Regressions:  
Weighted Number of Biotech Patents Acting as Dependent Variable 
  Model1 Model2 Model3 Model4 Model5  Model6 
Biotech portfolio  0.0046***  0.0039*** 0.0044*** 0.0039*** 0.0040***  0.0045*** 
  (0.0009) (0.0010) (0.0010) (0.0010) (0.0010)       (0.0010)
R&D expenditures 0.0004***  0.0003*** 0.0004*** 0.0003*** 0.0004*** 0.0004*** 
  (0.0001) (0.0001) (0.0001) (0.0001) (0.0001)       (0.0001)
Clusters   0.1015**  0.0991**  0.3962***  
   (0.0455)  (0.0471)  (0.1005)   
Clusters²       -0.0492***   
       (0.0147)   
Other regions      0.0152  0.004  -0.0457   
     (0.0194)  (0.0201)  (0.0377)   
Other  regions²       0.0033   
       (0.0021)   
Countries        -0.0296 
              (0.0976)
Countries²        0.008 
              (0.0114)
Time  dummies  yes yes yes yes yes  yes 
Constant 0.1621  0.0437  0.131 0.0376  -0.1544 0.1845 
  (0.1545) (0.1638) (0.1602) (0.1668) (0.1845)       (0.2088)
Number  Obs  422 422 422 422 422  422 
Wald Chi²  125.61***  133.31*** 127.82*** 133.67*** 150.32***  130.96*** 
Remarks: Standard errors are reported between parentheses; 
*, **, *** indicate significance at the 10%  
5% and 1% levels 
  
  
  36